Eliea Wellness
Scientific Validation

Evidence-Based Dermatology

Our formulations are rigorously tested for efficacy and safety. We believe in transparency and data-driven development.

Biological Support

01

In-vitro Screening

Initial screening of bioactive ingredients using cell cultures to determine cytotoxicity and cellular uptake efficiency.

02

Clinical Trial

Double-blind, placebo-controlled studies on human volunteers to measure visible skin and hair improvements.

03

Dermatological Evaluation and Product Safety Test

Human Repeat Insult Patch Test (HRIPT) and Primary Irritation Patch Test (PIPT) on human volunteers, approved by Dermatologists.

Mechanism of Action: Bioépicrone™

Targeted Therapy

Inhibition of Androgenic Alopecia (AGA)

Our latest study data confirms that Bioépicrone™ effectively downregulates SRD5A Type-2 by 22.9%. This enzymatic downregulation is critical in reducing the excessive conversion of testosterone to di-hydrotestosterone (DHT).

SRD5A2 (gene) - HFDPC (24hr)

SRD5A2 relative expression
1.5 %
1.0 %
0.5 %
0.0 %
Control
0.3 %
22.9%
3%

Molecular Pathway Intervention

Testosterone
Bioépicrone™ Downregulates
SRD5A Type-2
DHT Production
Prevents DHT-AR Activation
Healthy Follicle Growth
Targeted Therapy

Inhibition of Alopecia Areata (AA)

Bioépicrone™ inhibits JAK3 signaling by 43.1%, thus treating Alopecia Areata (AA).

JAK3 (gene) - HFDPC (24hr)

JAK3 relative expression
1.5 %
1.0 %
0.5 %
0.0 %
Control
0.3 %
43.1%
3%

Molecular Pathway Intervention

Activated CD8+T cells,NK cells
Bioépicrone™ Downregulates
JAK3 Activation
Alopecia Areata
Targeted Therapy

Reduction of Acne Formation

Bioépicrone™ downregulates MC5R and SRD5A1 by 64.5% and 14.9% respectively, preventing excessive conversion of testosterone to di-hydrotestosterone (DHT). Thus, reducing excessive sebum production helpful in the treatment of Acne.

MC5R (gene) - PCi-SEB

MC5R Relative Expression
1.5 %
1.0 %
0.5 %
0.0 %
Control
0.01 %
64.5%
0.1%

SRD5A1 (gene) - PCi-SEB

SRD5A1 Relative Expression
1.5 %
1.0 %
0.5 %
0.0 %
Control
0.01 %
14.9%
0.1%

In-vitro Assessment of Bioépicrone™

Summary of efficacy data obtained from recent trials using human iPSC-derived models and HFDPC cultures.

Study ID Compound Focus Area Study Model Results Testing Facility
DC.760.09.032 Bioépicrone™ 3% Alopecia Areata Human Follicle Dermal Papilla Cells (HFDPC) Inhibition of Janus Kinase 3 (JAK3) by 43.1% DermaclaimLab S.L., Valencia (España)
DC.760.09.032 Bioépicrone™ 3% Androgenic Alopecia Human Follicle Dermal Papilla Cells (HFDPC) Down-regulation of Steroid 5-alpha reductase type 2 (SRD5A2) by 22.9% DermaclaimLab S.L., Valencia (España)
DC.618.13.057 Bioépicrone™ 0.1% Acne Human iPSC-derived Sebocytes (PCI-SEB) Down-regulation of Melanocortin 5 Receptor (MC5R) by 64.5% DermaclaimLab S.L., Valencia (España)
DC.618.13.057 Bioépicrone™ 0.1% Acne Human iPSC-derived Sebocytes (PCI-SEB) Down-regulation of SRD5A1 by 14.9% DermaclaimLab S.L., Valencia (España)

Publications & White Papers

2024 Product Efficacy Report

Detailed analysis of our 2024 formulary updates.

Request Access
×

Contact Us